Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet
Authors:
- 3 February 2025
- journal article
- review article
- Published by Elsevier in The Lancet Haematology
- Vol. 12 (2) , e138-e150
Abstract
No abstract availableKeywords
Funding Information
- European Commission
This publication has 48 references indexed in Scilit:
- Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma PatientsClinical Lymphoma Myeloma and Leukemia, 2021
- Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trialeJHaem, 2020
- Prognostic role of ΔMTV and ΔTLG in Burkitt lymphomaAnnals of Nuclear Medicine, 2019
- Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimensAnnals of Hematology, 2017
- In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective studyAnnals of Hematology, 2017
- Outcomes of adults with relapsed or refractory Burkitt and high‐grade B‐cell leukemia/lymphomaAmerican Journal of Hematology, 2017
- Dose‐intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection statusCancer, 2013
- Sporadic childhood Burkitt lymphoma incidence in the United States during 1992–2005Pediatric Blood & Cancer, 2009
- Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancerCancer, 2003